Z-Phe-Arg-AFC
| Code | Size | Price |
|---|
| AG-CP3-0028-M005 | 5 mg | £65.00 |
Quantity:
| AG-CP3-0028-M025 | 25 mg | £235.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Z-FR-AFC . TFA
Appearance:
White to off-white solid.
CAS:
93753-73-2 (free base)
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.
InChi:
InChI=1S/C33H33F3N6O6.C2HF3O2/c34-33(35,36)24-18-28(43)48-27-17-22(13-14-23(24)27)40-29(44)25(12-7-15-39-31(37)38)41-30(45)26(16-20-8-3-1-4-9-20)42-32(46)47-19-21-10-5-2-6-11-21;3-2(4,5)1(6)7/h1-6,8-11,13-14,17-18,25-26H,7,12,15-16,19H2,(H,40,44)(H,41,45)(H,42,46)(H4,37,38,39);(H,6,7)/t25-,26-;/m0./s1
InChiKey:
FLPBOIDNDJASFK-CCQIZPNASA-N
Long Description:
Chemical. CAS: 93753-73-2 (free base). Formula: C33H33F3N6O6 . C2HF3O2. MW: 666.7 . 114.0. Synthetic. Fluorogenic substrate, specifically used to determine the enzyme activity of Cathepsin L. Useful for the study of cathepsin activity and for screening small molecule inhibitors for drug discovery and HTS applications. Likely to be cleaved by cathepsins B, F, K, S and L, cathepsins L-like proteases and proteases such as papain, cruzipain, plasma kallikrein, soybean trypsin-like enzyme and the falcipains-1 and -2 (malaria hemoglobinases). Hydrolysis of this substrate is monitored by observing fluorescence at an Excitation of 400nm and Emission at 505nm.
Molecular Formula:
C33H33F3N6O6 . C2HF3O2
Molecular Weight:
666.7 . 114.0
Package Type:
Plastic Vial
Product Description:
Fluorogenic substrate, specifically used to determine the enzyme activity of Cathepsin L. Useful for the study of cathepsin activity and for screening small molecule inhibitors for drug discovery and HTS applications. Likely to be cleaved by cathepsins B, F, K, S and L, cathepsins L-like proteases and proteases such as papain, cruzipain, plasma kallikrein, soybean trypsin-like enzyme and the falcipains-1 and -2 (malaria hemoglobinases). Hydrolysis of this substrate is monitored by observing fluorescence at an Excitation of 400nm and Emission at 505nm.
Purity:
>95% (HPLC)
Sequence:
Z-Phe-Arg-7-amino-4-trifluoromethylcoumarin
SMILES:
[NH3+]C(NCCC[C@@H](C(NC1=CC=C(C(C(F)(F)F)=CC(O2)=O)C2=C1)=O)NC([C@H](CC3=CC=CC=C3)NC(OCC4=CC=CC=C4)=O)=O)=N.FC(F)(C([O-])=O)F
Solubility Chemicals:
Soluble in DMSO. Moderately soluble and highly stable in water-based solvents.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
References
New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase: T. Morita, et al.; J. Biochem. 82, 1495 (1977) | Separation and identification of cathepsins in newborn rat epidermis: R.J. Harvima, et al.; J. Invest. Dermatol. 88, 393 (1987) | Preliminary studies on cysteine and serine proteinase activities in inflamed human gingiva using different 7-amino-4-trifluoromethyl coumarin substrates and protease inhibitors: S.W. Cox & B.M. Eley; Arch. Oral Biol. 32, 599 (1987) | Photometric or fluorometric assay of cathepsin B, L and H and papain using substrates with an aminotrifluoromethylcoumarin leaving group: J.R. Tchoupe, et al.; Biochim. Biophys. Acta 1076, 149 (1991) | Developmentally regulated secretion of cathepsin L-like cysteine proteases by Haemonchus contortus : M.L. Rhoads & R.H. Fetterer; J. Parasitol. 81, 505 (1995) | Taenia saginata Oncosphere Excretory/Secretory Peptidases: A. Clinton White, Jr. ; J. Parasitol. 82, 7 (1996) | Human cathepsin F: expression in baculovirus system, characterization and inhibition by protein inhibitors: M. Fonovic, et al.; Biol. Chem. 385, 505 (2004) | Identification and biochemical characterization of vivapains, cysteine proteases of the malaria parasite Plasmodium vivax : B.-K. NA, et al.; Biochem. J. 378, 529 (2004) | Crosstalk between the ubiquitin-proteasome system and autophagy in a human cellular model of Alzheimer's disease: V. Cecarini, et al.; Biochim. Biophys. Acta 1822, 1741 (2012) | Cysteine Protease Inhibitor (AcStefin) Is Required for Complete Cyst Formation of Acanthamoeba: J-Y. Lee, et al.; Eukaryot. Cell 12, 567 (2013) | Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype: V.A. Fajardo, et al.; Dis. Model Mech. 8, 999 (2015) | Data on skeletal muscle apoptosis, autophagy, and morphology in mice treated with doxorubicin: T.L. Campbell, et al.; Data Brief 7, 786 (2016) | Sarcolipin deletion exacerbates soleus muscle atrophy and weakness in phospholamban overexpressing mice: V.A. Fajardo, et al.; PLoS One 12, e0173708 (2017)
Related Products
| Product Name | Product Code | Supplier | Ac-Arg-Leu-Arg-AMC | AG-CP3-0013 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boc-Leu-Arg-Arg-AMC | AG-CP3-0014 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z-Leu-Leu-Nva-CHO [MG-115] | AG-CP3-0015 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Suc-Leu-Leu-Val-Tyr-AMC | AG-CP3-0016 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z-Leu-Leu-Leu-AMC | AG-CP3-0019 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Z-Leu-Leu-Glu-AMC | AG-CP3-0022 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||